Tumor Registry Pancreatic Cancer

Completed

• Conditions: Pancreas Cancer

• Registration Number: NCT02089269
• Lead Sponsor: iOMEDICO AG

Brief Summary

The registry aims to collect and analyse information on the antineoplastic treatment of patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention (cohort 1) and patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention (cohort 2) in daily routine practice in Germany. The registry will follow up patients for two years. It will identify common sequences of treatments used as well as changes in the treatment of the disease. Health-related quality of life will be analysed during the course of the treatment (PanLife). Based on the available data a prognostic score will be developed.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-12
• Study First Submitted: 2014-03-14
• Study First Submitted QC: 2014-03-14
• Study First Posted: 2014-03-17
• Primary Completion: 2022-04-14
• Study Completion: 2024-06
• Status Verified: 2024-10
• Last Update Submitted: 2025-01-28
• Last Update Posted: 2025-03-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2325

Inclusion Criteria

• resectable or locally advanced/metastatic pancreatic cancer
• 18 years and older
• Antineoplastic treatment
• Date of consent no later than 2 weeks after start of first-line treatment

Exclusion Criteria

• No pancreatic cancer
• Below 18 years and older
• No antineoplastic treatment
• Date of consent later than 2 weeks after start of first-line treatment

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Treatment reality in Germany	over 5 years	description of treatments selected for patients per line of therapy over the course of the project

Trial Locations

Locations (1)

iOMEDICO; 🇩🇪 Freiburg, BW, Germany